Amgen Should Win Patent Suit, Analyst Says

Law360, New York (January 22, 2007, 12:00 AM EST) -- Amgen Inc. is likely to win its long-running patent suit against Roche Holding AG, according to a report issued Monday by Bear Stearns & Co. Inc.

In the report, Bear Stearns analyst Mark Schoenebaum cited court documents that said Roche’s anemia drug Mircera had the same “amino acid sequence and composition” as Amgen’s drug Epogen.

“In our opinion, it will be difficult for Roche to argue that [Mircera’s] backbone falls outside the scope of Amgen’s patents on Epo and believe Amgen will be able to argue...
To view the full article, register now.